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Background: Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing
ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to
reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers.
Methods: Pubmed, Medline and Scopus were searched to select English-language articles. Two investigators
independently extracted characteristics and results of selected studies. Articles were included only if prospective
and if absolute numbers of ovarian cancer and death events were available or derivable from the test. Pooled
hazard ratio (HR) with 95% confidence interval (CI) was calculated using fixed effects model.
Results: Meta-analysis of 3 prospective studies demonstrated a significant risk reduction of ovarian cancer with
RRSO in BRCA 1 and BRCA 2 mutation carriers, as well as benefit in all-causes mortality incidence.
Conclusions: It may be justified to recommend RRSO to reduce ovarian cancer risk and all-causes mortality in
women with a mutation in BRCA 1 and BRCA 2.
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Women with a germline mutation in BRCA 1 and BRCA 2
genes are at substantially elevated lifetime risk of developing
ovarian cancer (15% – 56%) than the general population
(1.4%) [1-3]. Understanding genetic basic mechanisms of
disease has allowed the development of primary prevention
and risk-reducing salpingo-oophorectomy (RRSO) was
introduced with the aim of reducing risk ovarian cancer
(OC). Recently, empirical data confirms this hypothesis,
demonstrating OC reduction risk of 85% to 95% in these
patients [4]. Nowadays, women with BRCA 1 and BRCA 2
mutations are therefore strongly advised to have prophylactic
surgery once childbearing is complete [4].* Correspondence: clamarchetti@libero.it
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unless otherwise stated.The aim of this meta-analysis is to report the outcomes
of homogeneous prospective studies in order to define
conclusive results of RRSO impact in ovarian cancer
incidence and all-causes mortality and to help clinicians
and women in making cancer risk reduction decisions.Methods
Data extraction and studies selection
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was followed to
perform the meta-analysis. It includes studies without
any restrictions on publication date. The last search
was done on July 2014. Literature electronic databases
(Pubmed, Medline and Scopus) were searched for
“oophorectomy”, “salpingo-oophorectomy”, “prophylactic
oophorectomy”, “risk-reducing salpingo-oophorectomy”,
“ovarian cancer” and “BRCA” in title and abstract. Studies
that compared preventive oophorectomy with follow-upral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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were eligible. Prospective studies, written in English, were
included. Reference lists of previously published reviews
and meta-analyses were explored. Review articles, case
reports, commentaries and letters were not included.
Conference abstracts were not considered because of
the insufficient data provided by the authors.
Two independent reviewers (CM and FDF) selected
the identified studies based on the title and abstract. If
the study’s topic could not be ascertained from its title
or abstract, the full-text version would be retrieved for
evaluation. Disagreement was resolved by discussion or
consensus or with a third researcher (LM).
Studies were eligible if patients had a proven mutation
status, were cancer-free at study enter and had not previous
history of prophylactic surgery.
In the closer evaluation of potentially eligible articles,
because large collaborations are needed to study BRCA
1 and BRCA 2 carriers, many of the studies had overlapping
centers. When two articles appeared to report results with
overlapping data, only the data representing the most recent
publication or with the larger sample size were included
in the meta-analysis. Although we made every attempt to
eliminate redundancy in data represented in our
meta-analysis, we cannot rule out the possibility that a few
individuals participated on more than one study. From all
including studies were obtained: first author’ surname,
publication year, sample size of cases and controls,
treatment, duration of follow-up, detection rate.
For the subgroup analysis of OC risk reduction according
with gene-specific mutation, we chose the first experience
published by Finch et al. [5] in order to evaluate the
mutation specific data.
End-points
Primary end-point was the risk of developing OC; sec-
ondary end-point was the impact on all-causes mortality.
Moreover, all-causes mortality incidence was studied in
those patients who had or had not a history of breast
cancer; whereas, in these women, data analysis of OC
risk was excluded because there were dishomogeneous
data.
A subgroup analysis – in patients BRCA1 and BRCA2
mutated – was performed; this data analysis concern
two studies (4310 patients) but, as above mentioned, dueTable 1 Characteristic of prospective studies
Study (country) Patients with/without RRSO
All BRCA1
Kauff et al. [13] (USA) 509/283 325/173
Domchek et al. [10] (USA) 939/1678 681/1006
Finch et al. [6] (USA-Europe) 3513/2270 2649/1824
RRSO: prophylactic salpingo-oophorectomy.to lack of specific data in the update Finch et al. study
[6], we considered the previous one [5].
Statistical analysis
Cancer risk and mortality analysis were stratified by
studies and hazard ratio (HR). The pooled HR was cal-
culated using a fixed- or a random- effect models. Forest
plot were used for graphical representation of each study
and pooled analysis.
The size of every box represents the weight that the
corresponding study exerts in the meta-analysis; confi-
dence intervals of each study are displayed as horizontal
line through the box.
The pooled HR is symbolized by a solid diamond at
the bottom of the forest plot and the width of the square
represents the 95% CI of HR. HR, variance, 95% CI, log
[RR] and SE for each study were extracted or calculated
based on the published studies according to the methods
described by Tierney in 2007 [7]. A significant two-way
p-value for comparison was defined as p <0.05. Statis-
tical heterogeneity between studies was examined using
both the Cochrane Q statistic (significant at p <0.1) and
the I2 value (significant heterogeneity if >50%) [8]. Statis-
tical analysis was performed by Review Manager 5.0
(http://www.cochrane.org). Publication bias was exam-
ined using analyses described by Egger and Begg [9,10].
Results
The literature search identified a total of 265 potentially
relevant papers. Articles were excluded because of sub-
ject not related to the study (n = 171), review (n = 63),
editorial letter (n = 19). Three articles were eliminated
because have updated versions, whereas several studies
were excluded because retrospective (2 articles) and
case-control (1 article) [5,11,12]. Three prospective stud-
ies (9192 patients) were included in the final analysis
(Table 1) [6,13,14]. Flow chart of meta-analysis is shown
in Figure 1. Mean follow-up is 4.0 years. The χ2 tests for
heterogeneity of each comparison showed no significant
heterogeneity. No significant publication bias was found.
Risk-reducing salpingo-oophorectomy and ovarian cancer
risk
In all published studies, the RRSO consistently reduced





Figure 1 Flow chart of meta-analysis.
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p <0.00001) (Figure 2).
Risk-reducing salpingo-oophorectomy and all-causes
mortality
The all-cause mortality benefit associated with RRSO
was 0.32 (95% CI: 0.27 – 0.38, p <0.00001) for all popula-
tion (Figure 3). Among patients with or without previous
breast cancer the risk reduction of RRSO was similar, with
a modest benefit in patients without history of breast
cancer: 0.29 (95% CI: 0.19 – 0.46, p <0.00001) versus 0.32
(95% CI: 0.26-0.39, p <0.00001) (Figure 4).
BRCA subgroup analysis
The following analysis concerned two studies including
4310 patients with a mean follow-up of 4.8 years.
The HR of OC risk reduction was significantly lar-
ger in BRCA 1 subgroup (0.20; 95% CI: 0.12 – 0.32,
p <0.00001), whereas there was no significant benefit in
BRCA 2 patients (0.21; 95% CI: 0.02 – 1.91, p =0.22 )
(Figure 5).
All-cause mortality was equally strong for BRCA1
(HR, 0.31; 95% CI, 0.26 – 0.38, p <0.00001) and
BRCA2 mutation carriers (HR, 0.36; 95% CI, 0.25 – 0.52,
p <0.00001) (Figure 6).Figure 2 Forest plots of relative risk (RR) estimates for risk reduction of
in the overall population of BRCA 1 and BRCA 2 mutation carriers.Discussion
Despite extensive research efforts, consisting of 3 pro-
spective studies, 1 case control, 2 retrospective studies
and 1 meta-analysis, the role of RRSO in reducing the
risk of OC is still debated and safety concerns are still
discussed [5,6,11,13-15].
Our study tries to address this problem using the
standard methodology of meta-analysis, and formally
assessing the presence and sources of heterogeneity in
the results of the available studies. After the publication
of the previous meta-analysis by Rebbeck et al. [15], two
large-population studies have been published [6,13].
Therefore, a larger number of patients and exclusively
prospective studies have been considered in our meta-
analysis; consequently the statistical power has increased
and we have been able to evaluate not only the OC
risk reduction but also the all-cause mortality after
RRSO: finally we evaluated the effect of RRSO in the
overall population, as well as in BRCA 1 and BRCA 2
subgroups distinctly.
The importance of the observed reduction in the risk
of OC, resulting from RRSO, did not modify compared
to Rebbeck et al. [15] conclusions. Our results provide
convincing evidence for support the efficacy of RRSO
strategy with an HR of 0.19 (0.13 – 0.27), which meansovarian cancer associated with risk-reducing salpingo-oophorectomy
Figure 3 Forest plots of relative risk (RR) estimates for all-causes mortality associated with risk-reducing salpingo-oophorectomy in the
overall population of BRCA 1 and BRCA 2 mutation carriers.
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there was not heterogeneity between the studies (I =0%),
indicating a strong accordance in the results of these
prospective studies, and emphasizing the robustness of
benefit observed.
This advantage was present in patients, having either
BRCA 1 (HR 0.20; 95% CI, 0.12 – 0.32), or BRCA 2 (HR
0.21; 95% CI, 0.02 – 1.91) mutations even if in the latter
group a small number of patients may affect the strength
of evidences. The difference among BRCA 1 and BRCA
2 mutation carriers may also be explained by two
main reasons. First of all, in literature is reported a
low absolute number of BRCA 2-associated gynecologic
cancers [14]. Secondly, it is now well established that
among women with BRCA 2 mutation, the risk of
gynecologic cancer is only 2% to 3% by the mean age
of 50 years, while it increases in the late 30s in women
with BRCA 1 mutation [2,16].
This meta-analysis also examines a new aspect of
the RRSO: its impact on all-causes mortality. RRSO
assured a clear benefit, reducing mortality, both in
general population (HR, 0.32; 95% CI, 0.27 – 0.38)
and in its BRCA subgroups (HR, 0.31; 95% CI, 0.26 – 0.38
and HR, 0.36; 95% CI, 0.25 – 0.52 for BRCA 1 and
BRCA 2, respectively). The observation that RRSO has a
profound protective effect on all-causes mortality allows
significant reflections. Major concerns about RRSOa
b
Figure 4 Forest plots of relative risk (RR) estimates for all-causes mor
BRCA 1 and BRCA 2 mutation carriers without prior (a) and with prioprocedure comes from several data referred to general
population in which oophorectomy in women younger
than 45 years is associated with increased mortality [17].
Nonetheless, even if we can assume that the risk/benefit
ratio of RRSO is significantly different in BRCA 1 and
BRCA 2 mutation carriers than in the general population,
we should also admit that approximately 60% of women
with a BRCA 1 or BRCA 2 mutation is elected to undergo
RRSO between 35 and 40 years of age, thus before
menopause [18,19]. RRSO may negatively influence
patient’s quality of life and health, due to a dramatically
rapid decline in estrogen and androgen levels [17,20].
Surgical menopause can result in severe hot flashes,
vaginal dryness, sexual dysfunction, sleep disturbances and
cognitive changes as well as increased risk of cardiovascular
disease [21]. Therefore, even if our results could reassure
clinicians on health benefits of RRSO (cancer prevention)
also the risk of the procedure (quality of life and long-term
sequelae) should be mentioned.
With this regard, data on safety and feasibility of
hormonal replacement treatment (HRT) in oophorec-
tomized patients with BRCA 1 and BRCA 2 mutation
carriers are required. Despite the limitations of retrospect-
ive and prospective observational studies, short-term HRT
seems to improve quality of life and, moreover, does
not seem to have an adverse effect on oncologic outcomes
in BRCA 1 and BRCA 2 mutation carriers without atality associated with risk-reducing salpingo-oophorectomy in
r breast cancer (b).
ab
Figure 5 Forest plots of relative risk (RR) estimates for risk reduction of ovarian cancer associated with risk-reducing salpingo-oophorectomy
in BRCA 1 (a) and BRCA 2 (b) mutation carriers.
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randomized studies concerning type, timing, and length of
administration of HRT as well as its long-term effects on
the association between RRSO and cancer risk in BRCA 1
and BRCA 2 mutation carriers are mandatory.
Our study may be accompanied by some limitations.
Firstly, it was not possible to delineate a correct
standardization by age of RRSO procedure. The mean
age for RRSO was 46 years but a different age’s catego-
rized analysis was not possible, because only Finch et al.
[6] stratified results for age and the necessary data
are missing. Secondly, even if we found larger sam-
ples size distinguishing BRCA 1 from BRCA 2 muta-
tion carriers, information that can be drawn are still
insufficient, not allowing definitive conclusions especially
in BRCA 2 population. Thirdly, the mean follow up of the
analyzed studies is of nearby 4 years; reasonably, lon-
ger follow up would be useful to better understand
the impact of this procedure also in terms of quality
of life. Finally, only studies of prospective nature have
been analyzed because no randomized studies havea
b
Figure 6 Forest plots of relative risk (RR) estimates for all-causes mor
BRCA 1 (a) and BRCA 2 (b) mutation carriers.been published in this setting. Even if it is clear that
a randomized controlled study design would allow a
better evaluation of risk reducing surgery on cancer
risk and mortality reduction, it is generally accepted
that a randomized approach would neither be acceptable
nor ethical for the management of these patients and
therefore, this field of research is limited to undertak-
ing observational studies, with intrinsic methodological
limitations [13].
Briefly, RRSO is highly effective in reducing OC,
both BRCA 1 and BRCA 2 mutation carriers. Long-term
follow up data as well as data from studies concerning the
management of oophorectomized BRCA 1 and BRCA 2
mutation carriers patients are needed to further confirm.
Conclusion
This meta-analysis provides an analysis of the benefit of
RRSO – in term of ovarian cancer risk incidence and
all-causes mortality – in patients with BRCA 1 and BRCA
2 mutation. Results could be used as reference data for
clinical studies and clinical management.tality associated with risk-reducing salpingo-oophorectomy in
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